Dashboard Tools Market News Investing Ideas Pricing About Us
Sign Up
Log in
Evaxion Biotech A/S banner

Evaxion Biotech A/S
NASDAQ:EVAX

Watchlist Manager
Evaxion Biotech A/S Logo
Evaxion Biotech A/S
NASDAQ:EVAX
Watchlist
Price: 3.25 USD -4.41% Market Closed
Market Cap: $20.5m
Write Note Create Alert Ask AI
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

EVAX Price Targets Summary
Evaxion Biotech A/S

Wall Street analysts forecast EVAX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for EVAX is 12.58 USD with a low forecast of 10.1 USD and a high forecast of 16.8 USD.

EVAX Lowest Forecast
Wall Street Target
10.1 USD
211% Upside
EVAX Average Forecast
Wall Street Target
12.58 USD
287% Upside
EVAX Highest Forecast
Wall Street Target
16.8 USD
417% Upside
Lowest
Price Target
10.1 USD
211% Upside
Average
Price Target
12.58 USD
287% Upside
Highest
Price Target
16.8 USD
417% Upside
Evaxion Biotech A/S Competitors:
Price Targets
IPAR
Inter Parfums Inc
9% Upside
WOOF
Petco Health and Wellness Company Inc
47% Upside
ACIU
AC Immune SA
200% Upside
LVS
Las Vegas Sands Corp
24% Upside
IPAR
Inter Parfums Inc
9% Upside
WOOF
Petco Health and Wellness Company Inc
47% Upside
ACIU
AC Immune SA
200% Upside
LVS
Las Vegas Sands Corp
24% Upside
NCSM
NCS Multistage Holdings Inc
26% Upside

Revenue
Forecast

N/A
Past Growth
65% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
N/A
Past Growth
65% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

The compound annual growth rate of Evaxion Biotech A/S's revenue for the next 4 years is 65%.

What are analyst estimates?

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
0%
Average Beat
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
0%
Average Beat

What are analyst estimates?

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-93%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-93%
Average Miss

What are analyst estimates?

See Also

Summary
EVAX intrinsic value, competitors valuation, and company profile.
DCF Valuation
EVAX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
EVAX stock valuation using valuation multiples.
Wall Street Estimates
EVAX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
EVAX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is EVAX's stock price target?
Price Target
12.58 USD

According to Wall Street analysts, the average 1-year price target for EVAX is 12.58 USD with a low forecast of 10.1 USD and a high forecast of 16.8 USD.

What is Evaxion Biotech A/S's Revenue forecast?
Projected CAGR
65%

The compound annual growth rate of Evaxion Biotech A/S's revenue for the next 4 years is 65%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 317,100+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.